Full CoverageHims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
By Josh Nathan-kazis & Mackenzie Tatananni
Top news
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
By Annika Kim Constantino
Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Novo–Hims & Hers deal ends, Eli Lilly GLP-1 pill: What to know
All coverage
Hims Crashes After Novo Unexpectedly Yanks Collaboration Deal
By Allison Gatlin
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
By Stine Jacobsen & Amina Niasse
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
By Steve Gelsi
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
By Mary Cunningham
Novo Exits Hims Partnership, Citing Concerns Over Compounded Drugs
By Naomi Kresge & Madison Muller
Novo sends Hims packing
By Bryce Elder
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff’ Wegovy
By Grace Snelling
Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup
By Peter Loftus & Robb M. Stewart
Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility
By Edmund Ingham
Hims & Hers on track for biggest drop ever after Novo Nordisk ends partnership
By J. Edward Moreno Del Angel
Novo abruptly ends obesity drug deal with Hims
By Jonathan Gardner
Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug
By Louise Rasmussen
Wegovy Maker Novo Nordisk Dumps Hims & Hers Relationship Over Claims of Deceptive Marketing
By Luke Funk
Novo Nordisk ends partnership with Hims & Hers over Wegovy copycats
By Nathaniel Weixel
HIMS INVESTIGATION ALERT: Investigation Launched into Hims & Hers Health, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
By Robbins Geller Rudman
Novo Nordisk dropping Hims could boost other GLP-1 providers
By Katherine Davis
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
By Patrick Temple-West & Michael Peel
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
By Anjalee Khemlani
Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade
Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?
By Wajeeh Khan
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
By Allison Gatlin
Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade
Novo abruptly ends obesity drug deal with Hims
By Jonathan Gardner